Infliximab combined with purine analogues vs purine analogues
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
1 finding from 1 review
- Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes onlyRR 0.47 [0.15, 1.49]1 study · 115 participantsVery low